According to a study published Tuesday, July 6 and relating to nearly 11,000 patients, a class of anti-inflammatory drugs, including in particular tocilizumab, effectively reduces the risk of death in hospitalized patients of COVI-19.
The World Health Organization (WHO) recommended yesterday, July 6, their use, at the same time as corticosteroids, in serious COVID-19 cases yesterday, July 6, she announced several press agencies.
In Tunisia, tocilizumab is marketed under the name of Actemra or Roactemra according to the markets where it is sold. It is manufactured by the Swiss giant Roche Pharma in the form of an injectable solution for infusion.
According to the WHO which cites the results of this study, tocilizumab combined with corticosteroids, reduces mortality and the threat of respiratory assistance.
According to a study published Tuesday on dozens of clinical tests with nearly 11,000 patients, the administration of tocilizumab or sarilumab, with corticosteroids, makes it possible to reduce death by almost 20% compared to patients who are only cared for with corticosteroids.
The article Coronavirus: WHO recommends this medication appeared first on webdo.
